SecBot SecBot

VALN drug pipeline

Valneva SE · 2 rated drugs
$5.65
−0.2% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
2
1 bearish · 1 neutral
Phase 3 trials
1
1 with results posted

Drugs

soonest catalyst first
▼ bearish
Impact
PhaseApproved
Time to marketAlready approved and marketed in the EU, Canada, Brazil and select other markets (approved November 2023 in the US, but US and UK authorizations have been withdrawn).

IXCHIQ chikungunya vaccine (live attenuated) Updated Nov 15

What to watch

IXCHIQ's commercial future hinges on whether Valneva can rebuild regulatory trust after the US and UK withdrawals. The positive five-year durability data (94% seroresponse) supports the vaccine's efficacy case, but safety concerns remain the dominant overhang. Valneva reports nine-month 2026 results on November 24, which will provide the clearest read on IXCHIQ's ongoing revenue contribution from EU, Canada and Brazil markets.

Bull case
  • First-to-market advantage: IXCHIQ was the first FDA-approved chikungunya vaccine and remains approved in the EU, Canada, Brazil and other markets.
  • Durable efficacy: Five-year follow-up data (November 2026) showed 94% of recipients maintained neutralizing antibody titers above the seroresponse threshold after a single dose.
  • Comparable protection in elderly: Antibody persistence in adults 65+ was comparable to younger adults, supporting use in the highest-risk age group.
Bear case
  • US market lost: FDA suspended the license in August 2025 after reports of serious adverse events including encephalitis deaths; Valneva voluntarily withdrew the BLA/IND in January 2026.
  • UK market revoked: MHRA revoked marketing authorization in October 2026 after a benefit-risk review found risks outweighed benefits for travelers.
  • Safety overhang: Serious adverse events consistent with chikungunya-like illness, including hospitalizations and deaths, primarily in older adults with underlying conditions, have damaged the product's reputation.
● neutral
Impact
PhasePhase 2
Time to marketAt least 4-6 years away. The vaccine is in Phase 2 with no Phase 3 trial started or announced. Valneva is still evaluating next steps after the November 2026 readout. A pivotal Phase 3 program, if initiated, would take several years to complete before any regulatory filing.

S4V2 shigella tetravalent bioconjugate vaccine Updated Nov 15

What to watch

S4V2's positive Phase 2 readout is already public and priced into the stock to some degree (VALN rose ~5% on the news). The next meaningful catalyst is Valneva's decision on whether and how to advance S4V2 into Phase 3, which could come alongside the November 24, 2026 nine-month results or at a later R&D day. For now, S4V2 is a long-duration pipeline option with no near-term binary event; Valneva's stock will be driven more by IXCHIQ commercial traction, the Pfizer-partnered Lyme vaccine's regulatory progress, and the company's cash runway.

Bull case
  • S4V2 is the world's most clinically advanced tetravalent bioconjugate vaccine candidate against shigellosis, a disease with no approved vaccine and high unmet need globally
  • Phase 2 results were positive across both adult CHIM (efficacy signal) and infant (immunogenicity/safety) trials simultaneously, de-risking the program significantly
  • FDA granted Fast Track designation in October 2024, which can accelerate development and review
Bear case
  • No Phase 3 trial has been initiated or even formally designed; Valneva is still evaluating the development path, meaning meaningful clinical data is years away
  • Valneva faces significant financial constraints: the company cut its 2026 revenue outlook and workforce after Q1 sales dropped 40%, and the stock trades near its 52-week low of $4.75
  • S4V2 is a small part of Valneva's pipeline; the company's near-term value drivers are the Pfizer-partnered Lyme vaccine (VLA15) and the approved IXCHIQ chikungunya vaccine, not S4V2

Other drugs in filings and trials

no drug report yet

Clinical trials

2 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
VLA1553 full doseA Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 YearsPhase 2Completed · results304Jul 31, 2024
ActiveA Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in AdolescentsPhase 3Completed · results754Mar 14, 2023